Research programme: angiopoietin-like protein 3 inhibitors - Daiichi Sankyo
Alternative Names: ANGPTL 3 inhibitors programmeLatest Information Update: 14 May 2008
At a glance
- Originator Daiichi Sankyo Company
- Class
- Mechanism of Action Angiopoietin inhibitors; Lipoprotein lipase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo
- 18 Nov 2003 Preclinical trials in Atherosclerosis in Japan (unspecified route)
- 18 Nov 2003 Preclinical trials in Hyperlipidaemia in Japan (unspecified route)